Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer

Small-cell Lung Cancer Clinical Trial

— DRIVE  

Official title:

Durvalumab in Combination With Standard Chemotherapy for 1st Line Therapy of Patients With Extensive Stage Small Cell Lung Cancer: A Non-interventional, Prospective Observational Study of Clinical Practice, Quality of Life and Use of Health Resources in Real-world Clinical Practice (DRIVE)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05761977
• Other study ID #: HE1R/21
• Status: Recruiting
• Start date: March 31, 2021
• Est. completion date: April 2024

Study information

• Verified date: February 2023
• Source: Hellenic Cooperative Oncology Group
• Contact: Helena Linardou, MD
• Phone: +302104809339
• Email: elinardou[@]otenet.gr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a non-interventional, multicenter, prospective observational study and registry of standard clinical practice in patients with Extensive Stage-Small Cell Lung Cancer (ES-SCLC) receiving 1st line treatment with Durvalumab in combination with standard chemotherapy (cisplatin or carboplatin + etoposide) in the approved indication, which will be carried out in Greece. In this study data will be collected prospectively based on real-world clinical practice. A prospective cohort of atients from centers of the Hellenic Cooperative Oncology Group (HeCOG) will be included. The study will be conducted in hospitals and by physicians specialized in lung cancer from different geographical areas of Greece.

Description:

In this observational prospective study, no changes to current therapeutic practice will be required and all aspects of treatment and clinical management of patients will be in compliance with the local clinical practice and will be left to the discretion of the participating physicians. Patients will be treated in accordance with the study medicine's local prescribing information and standard clinical practice as to the frequency of visits and types of evaluations carried out. The frequency of follow-up visits is set on the basis of standard practice; however, the study-related data will be collected during integration and during the routine clinical visits that will take place after the start of treatment. No visits or measurement/evaluation will be mandatory by the protocol and data collection at the predetermined time-points will be carried out only if the patient visits the center.

Patients will be enrolled during a 12-month recruitment period from HeCOG-participating public and private centers/clinics in Greece with specialization in lung cancer. As part of this study, participating physicians will be asked to follow up each patient for an additional 12 months of treatment at most after last subject is included, or until death, withdrawal of consent, discontinuation of treatment or initiation of new antineoplastic therapy, until completion of the study, or doctor's decision, whichever appears first. Therefore, the maximum period of prospective observation of the study will be 24 months (2 years) from the last patient enrolled in the study. This study will be conducted in accordance with the Guidelines for Good Pharmacoepidemiological Practice, the European General Data Protection Regulation (GDPR) and the applicable regulatory requirements.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: April 2024
• Est. primary completion date: April 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female patients, regardless of race (residents in Greece), no younger than 18 years old at the initiation of treatment.

• Patients with histologically or cytologically confirmed diagnosis of extensive Small Cell Lung Cancer (SCLC)

• Patients who have not received prior systemic treatment for SCLC (chemotherapy or immunotherapy)

• Patients for whom the decision to administer treatment with Durvalumab+chemotherapy has already been taken before their inclusion in the study and is clearly separated from the decision of the physician for the patient's participation in the current study.

• Patients who have provided informed signed consent to participate in the study and to collect and analyze medical data related to the objectives of this study.

Exclusion Criteria:

• Patients with current diagnosis of primary cancer other than SCLC who require systemic or other treatment.

• Patients who have previously received chemotherapy or immunotherapy for SCLC

• Patients who are currently receiving or are expected to receive treatment with an investigational drug/medical device/intervention or who have received an investigational medicinal product within 1 month or 5 years half-life of the research agent (whichever is longer) before their initiation in this study.

Related Conditions & MeSH terms

• Extensive-stage Small-cell Lung Cancer
• Lung Neoplasms
• Small Cell Lung Carcinoma
• Small-cell Lung Cancer

Locations

Country	Name	City	State
Greece	Metropolitan Hospital	Néo Fáliro

Sponsors (1)

Lead Sponsor	Collaborator
Hellenic Cooperative Oncology Group

Country where clinical trial is conducted

Greece, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival rates (OS)	The primary objective of the study is to estimate the overall survival rates (OS) at 6,12 and 24 months for patients with extensive small-cell lung cancer treated with Durvalumab in combination with standard 1st-line chemotherapy with platinum-etoposide(cisplatin or carboplatin).	up to 24 months
Secondary	Progression free survival (PFS)	Evaluation of PFS from investigator	in 6, 12 and up to 24 months
Secondary	Overall response rate (ORR)		in 6 and up to 12 months
Secondary	Disease Control Rate		in 6 and up to 12 months
Secondary	time to reach a response (TTR)		up to 12 months
Secondary	duration of the response (DoR)		up to 12 months
Secondary	Assessment of patients characteristics with overall survival 12 months		up to 12 months
Secondary	Assessment of patients characteristics with overall survival 24 months		up to 24 months
Secondary	time under treatment (ToT)		up tp 24 months
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 with standard of care 1st line treatment		From date of Informed Consent signatory and every 3 weeks, up to 24 months
Secondary	Quality of life EQ-5D		From date of Informed Consent signatory and every 2 months, up to 24 months
Secondary	number of participants using health resources in daily clinical practice		From date of Informed Consent signatory and every 3 weeks, up to 24 months